Analysts Lower BioMarin Price Targets After Q3 Earnings
Oppenheimer cut its target to $94 from $97, RBC to $60 from $62, and Wedbush to $89 from $94. All three firms maintained their existing ratings.
Following BioMarin Pharmaceutical's third-quarter 2026 earnings release, several analysts adjusted their price targets for the company. Oppenheimer maintained an Outperform rating while lowering its price target to $94 from $97. RBC Capital maintained a Sector Perform rating and reduced its target to $60 from $62. Additionally, Wedbush kept an Outperform rating but trimmed its price target to $89 from $94.
These adjustments reflect analyst reactions to the company's recent financial performance and updated 2026 guidance.